Supplementary Table S1-S14 from Genomic and Epigenomic Analysis of Plasma Cell-Free DNA Identifies Stemness Features Associated with Worse Survival in Lethal Prostate Cancer

Table S1. Patient characteristics. Table S2. Patients-level clinical treatment and outcome details. Table S3. Mutations detected in patient cell-free DNA by EnhanceAR-Seq. Table S4. Copy number alterations detected in patient cell-free DNA by EnhanceAR-Seq. Table S5. Structural variations detected in patient cell-free DNA by EnhanceAR-Seq. Table S6. Cox regression for progression-free survival with baseline covariates including altered AR enhancer detected in pre-treatment plasma. Table S7. Cox regression for overall survival with baseline covariates including altered AR enhancer in pre-treatment samples. Table S8. Clinical characteristics of the metastatic prostate cancer cohort. Table S9. Patient plasma cell-free DNA methylation sequencing metrics. Table S10. Hypomethylated DMRs in AR/enhancer altered lethal mCRPC patients. Table S11. Hypermethylated DMRs in AR/enhancer altered lethal mCRPC patients. Table S12. Central coverage of transcription factor binding sites (TFBSs) for most accessible transcription factors in AR/enhancer altered lethal mCRPC. Table S13. Central coverage of transcription factor binding sites (TFBSs) for least accessible transcription factors in AR/enhancer altered lethal mCRPC. Table S14. Multivariate Cox regression for progression-free survival.